Literature DB >> 27434893

Optical Coherence Tomography and Multifocal Electroretinography in Diabetic Macular Edema: A Neurovascular Relation With Vision.

B N Nagesh, Brijesh Takkar, Shorya Azad, Rajvardhan Azad.   

Abstract

BACKGROUND AND OBJECTIVES: To evaluate retinal neuropathy in patients with diabetic macular edema (DME) with multifocal electroretinograph (mfERG), and to evaluate the simultaneous impact of retinal neuropathy and vasculopathy on visual acuity in subtypes of DME. PATIENTS AND METHODS: This prospective, controlled, investigative study conducted at a tertiary eye care center of Northern India included 79 eyes of 50 treatment-naïve patients with DME (Group 1), 94 eyes of 50 diabetic patients without diabetic retinopathy (Group 2), and 100 eyes of 100 normal volunteers as controls. Comprehensive ocular evaluation along with mfERG and optical coherence tomography (OCT) were performed for all patients. N1 and P1 mfERG waveforms in the two central-most rings of macula were evaluated for amplitudes and implicit time. OCT was used to sub-classify types of DME and evaluate macular thickness, ellipsoid zone (EZ), and external limiting membrane (ELM) disruption. Best-corrected visual acuity (BCVA) relative to other variables was the primary outcome measure. The three groups were compared for all the parameters inclusive of OCT and mfERG patterns. Further, OCT subtypes of DME were analyzed for mfERG waveform patterns.
RESULTS: All mfERG values were significantly lower in Group 1 and Group 2 as compared to Group 3 (P < .05). BCVA strongly correlated with central macular thickness, EZ, and ELM disruption scores in Group 1 (P = .001), but correlated modestly with mfERG waveform amplitudes in Group 1 patients with intact EZ and ELM only. BCVA correlated with mfERG amplitudes in patients with neurosensory detachment, but not in those with cystoid macular edema.
CONCLUSIONS: Neural changes set in before the clinical changes related to vasculopathy manifest in diabetic patients. Neuroretinopathy in patients with DME affects all retinal layers symmetrically in early stages, but impacts the middle retinal layers severely in advanced disease form. BCVA correlates with electrophysiological changes till the time morphological features are visible when stronger correlation is seen with anatomical disruption. [Ophthalmic Surg Lasers Imaging Retina. 2016;47:626-631.]. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh:

Year:  2016        PMID: 27434893     DOI: 10.3928/23258160-20160707-03

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging Retina        ISSN: 2325-8160            Impact factor:   1.300


  5 in total

Review 1.  Diabetic retinal neurodegeneration as a form of diabetic retinopathy.

Authors:  Deepak Soni; Pradeep Sagar; Brijesh Takkar
Journal:  Int Ophthalmol       Date:  2021-05-06       Impact factor: 2.031

2.  Interleaved Optical Coherence Tomography: Clinical and Laboratory Biomarkers in Patients with Diabetic Macular Edema.

Authors:  Corina-Iuliana Suciu; Vlad-Ioan Suciu; Ancuţa Cuţaş; Simona Delia Nicoară
Journal:  J Pers Med       Date:  2022-05-09

3.  Multifocal electroretinogram in diabetic macular edema and its correlation with different optical coherence tomography features.

Authors:  Hassan Khojasteh; Hamid Riazi-Esfahani; Elias Khalili Pour; Hooshang Faghihi; Fariba Ghassemi; Fatemeh Bazvand; Raziyeh Mahmoudzadeh; Mirataollah Salabati; Masoud Mirghorbani; Mohammad Riazi Esfahani
Journal:  Int Ophthalmol       Date:  2019-11-11       Impact factor: 2.031

Review 4.  Photoreceptor cells and RPE contribute to the development of diabetic retinopathy.

Authors:  Deoye Tonade; Timothy S Kern
Journal:  Prog Retin Eye Res       Date:  2020-11-12       Impact factor: 19.704

5.  Effects of Intravitreal Aflibercept on Retinal Function and Improvement of Macular Edema Associated With Diabetic Retinopathy.

Authors:  Atsushi Ichio; Masahiko Sugimoto; Hisashi Matsubara; Daiki Mochida; Kumiko Kato; Mineo Kondo
Journal:  Transl Vis Sci Technol       Date:  2020-10-06       Impact factor: 3.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.